Oncotarget

Research Papers:

Unfavorable efficacy to 131I ablation in BRAFV600E mutant papillary thyroid carcinoma with positive TgAb

Na Zhang, Jun Liang _ and Yan-song Lin

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:97407-97415. https://doi.org/10.18632/oncotarget.22129

Metrics: PDF 534 views  |   HTML 1618 views  |   ?  


Abstract

Na Zhang1, Jun Liang2,* and Yan-Song Lin1,*

1Department of Nuclear Medicine, Peking Union Medical College Hospital, Beijing 100730, China

2Department of Oncology, Peking University International Hospital, Beijing 102206, China

*These authors have contributed equally to this work

Correspondence to:

Jun Liang, email: liangjun1959@aliyun.com

Yan-Song Lin, email: linys@pumch.cn

Keywords: papillary thyroid carcinoma; BRAFV600E mutation; TgAb; radioiodine remnant ablation; efficacy

Received: June 22, 2017    Accepted: August 08, 2017    Published: October 26, 2017

ABSTRACT

The BRAFV600E mutation has shown a close relationship of aggressiveness in papillary thyroid carcinoma (PTC), while it remains unclear about its influence on the therapeutic response. As a common clinicopathologic risk factor, thyroglobulin antibody (TgAb) may have a correlation of prognosis in PTC. The objective was to investigate the relationship between BRAFV600E mutation and TgAb, and their combined effect on efficacy to radioiodine remnant ablation (RRA). This was a retrospective study including 298 PTC patients and they were divided into four groups according to the combined status. The BRAFV600E mutation rates declined along with increasing TgAb levels in the entire cohort. The ablative efficacy in terms of success or failure rate was statistically different among four groups (89.7%, 74.1%, 67.5%, 57.8%, respectively, P=0.009), group with both positive BRAF and TgAb presented the lowest efficacy. The combined status was associated with the poor efficacy to RRA independently (P=0.029). Among patients with positive TgAb, the effect of RRA in reducing TgAb level might be weakened in BRAF mutant status. The combined status of BRAFV600E mutation and positive TgAb predicts low efficacy to RRA and might be served as an independent unfavorable prognostic factor for PTC. BRAF mutant might weaken the effect of RRA in reducing TgAb levels in PTCs.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 22129